Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.59−0.07 (-10.00%)
Close on Nov 13, 2026Market cap $1.07MP/E –Yield –
Aptevo Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Aptevo Therapeutics's gross margin for the twelve months ending Dec 31, 2019 was 38.5%. For fiscal 2019 it was 38.5%, against 51.4% the year before. The highest annual figure on record is 65.8% in fiscal 2017.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 38.5% | −12.8 |
| FY2018 | Dec 31, 2018 | 51.4% | −14.4 |
| FY2017 | Dec 31, 2017 | 65.8% | +90.7 |
| FY2016 | Dec 31, 2016 | -24.9% | −74.5 |
| FY2015 | Dec 31, 2015 | 49.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | 32.1% | +2.4 |
| Q3 FY2019 | Sep 30, 2019 | 56.1% | −2.1 |
| Q2 FY2019 | Jun 30, 2019 | 18.7% | −44.2 |
| Q1 FY2019 | Mar 31, 2019 | 45.2% | −11.0 |
| Q4 FY2018 | Dec 31, 2018 | 29.7% | −3.0 |
| Q3 FY2018 | Sep 30, 2018 | 58.2% | −11.5 |
| Q2 FY2018 | Jun 30, 2018 | 62.9% | +130.1 |
| Q1 FY2018 | Mar 31, 2018 | 56.3% | −21.0 |
| Q4 FY2017 | Dec 31, 2017 | 32.7% | −9.4 |
| Q3 FY2017 | Sep 30, 2017 | 69.7% | +115.6 |
| Q2 FY2017 | Jun 30, 2017 | -67.2% | – |
| Q1 FY2017 | Mar 31, 2017 | 77.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 42.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -46.0% | – |
See a number that looks wrong?